Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism.

Authors :: Mishima M
Yabe T
Kondo T
Fujimoto K
Takata R
Yokoyama H
Niida Y
Tanaka T
Miyazawa K
Furuichi K
Source :: Clinical case reports [Clin Case Rep] 2024 Sep 05; Vol. 12 (9), pp. e9416. Date of Electronic Publication: 2024 Sep 05 (Print Publication: 2024).
Publication Year :: 2024
Abstract: CYP3A4 and CYP3A5 are the most abundant and important enzymes of the CYP3A subfamily, distributed in the liver, intestinal mucosa and kidney, and involved in tacrolimus metabolism. Here, we report a case of tacrolimus dosage refractoriness due to a genetic polymorphism of CYP3A5.<br />Competing Interests: The authors state that the study was conducted without any commercial or financial relationships that could be interpreted as a conflict of interest.<br /> (© 2024 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd.)

Full Text Access

Tools